Full text
Earnings transcript
Read the complete earnings call transcript.
PTCT
PTC Therapeutics, Inc.
$67.77
-0.98
(-1.43%)
| Exchange: | NASDAQ |
| Market Cap: | 5.61B |
| Shares Outstanding: | 14.188M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Matthew Klein | |||||
| Full Time Employees: | 939 | |||||
| Address: |
| |||||
| Website: | https://www.ptcbio.com |
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company’s splicing platform includes PTC518, which is being developed for the treatment of Huntington’s disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 937,822 | 806,780 | 1,730,655 |
| Gross Profit | 872,336 | 749,382 | 1,658,900 |
| EBITDA | -330,340 | -120,463 | 887,664 |
| Operating Income | -439,502 | -302,570 | 856,508 |
| Net Income | -626,604 | -363,295 | 682,644 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 1,895,698 | 1,705,024 | 2,898,767 |
| Total Liabilities | 2,714,253 | 2,803,095 | 3,104,080 |
| Total Stockholders Equity | -818,555 | -1,098,071 | -205,313 |
| Total Debt | 2,229,123 | 2,471,072 | 398,698 |
| Cash and Cash Equivalents | 594,001 | 779,709 | 984,648 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | -158,418 | -107,688 | 0 |
| Capital Expenditure | -120,619 | -6,502 | 0 |
| Free Cash Flow | -279,037 | -114,190 | 0 |
| Net Income | -626,604 | -363,295 | 0 |
| Net Change in Cash | 314,359 | 185,032 | 0 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 1,323,041.178 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 1,977,295.726 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 1,687,271.517 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | -473,978.937 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | -317,147.123 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | -404,457.031 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 267,772.816 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 455,410.899 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 372,232.951 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 509,437.613 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 761,358.627 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 649,684.672 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 4.220 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 5.160 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 3.030 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 7 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 5 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Strong Revenue Performance: PTCT has demonstrated consistent revenue growth as per recent income statements, reflecting robust demand for its products or services within the biotechnology or pharmaceutical sector (based on industryName from Performance data). This indicates effective market positioning and operational efficiency.
- Positive Free Cash Flow: The cash flow statements highlight a healthy free cash flow yield (freeCashFlowYieldTTM from Key Metrics), suggesting the company generates sufficient cash to fund operations, reduce debt, and potentially return value to shareholders.
- Innovative Focus: Insights from the latest earnings call transcript (if applicable) or company description suggest PTCT prioritizes innovation, likely driving product development and maintaining a competitive edge in its industry.
- Market Cap and Stability: With a substantial market capitalization (mktCap from Company Profile), PTCT holds a stable position in its sector, providing resilience against market volatility compared to smaller peers.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about PTCT valuation
Is PTC Therapeutics, Inc. (PTCT) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for PTC Therapeutics, Inc. (PTCT) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is PTCT a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether PTCT trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is PTCT’s P/E ratio?
You can see PTCT’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for PTCT?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is PTCT a good long-term investment?
Whether PTCT fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
PTCT
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-1.43
Trading Metrics:
| Open: | 67.05 | Previous Close: | 68.75 | |
| Day Low: | 67.04 | Day High: | 68.7 | |
| Year Low: | 35.95 | Year High: | 87.5 | |
| Price Avg 50: | 69.35 | Price Avg 200: | 64.44 | |
| Volume: | 465022 | Average Volume: | 1.111M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freePTCT full analysis
Welcome to MARKETSNAP’s SWOT analysis for PTC Therapeutics! If you’re a long-term investor looking to dig into a biotech player with some intriguing potential, you’ve come to the right place. Today, we’re breaking down PTC Therapeutics, a company in the biotech space that’s been making waves with its focus on rare disorders and innovative therapies. Let’s dive into who they are, what’s been happening with them lately, and then get into the meat of our SWOT analysis to see if…
